News

Along with the other Humira biosimilars, Hulio will not be on the market till 2023.

Peter Wehrwein, senior editor at Managed Healthcare Executive, spoke with Lisa Griffin, senior vice president of front-end operations at Jefferson Health in Philadelphia, about the pivot to telehealth, "seamless access" and racism.

The new plan, called Gravie Comfort, offers 100% coverage on most common healthcare services, including preventive care, primary care, specialist visits, labs and imaging, generic prescriptions, online care, and more – all at a cost comparable to most traditional group health plans.

Lowering the age and smoking history standards would result in substantially more Blacks and women being eligible for screening.

Gilead will present new data on virologic suppression in adults 65 years and older at AIDS 2020: Virtual this week.

The outlook for decreasing the maternal mortality rate in the country has recently improved as a result of a recent initiative by the Joint Commission, which has developed 13 new elements of performance (EOPs) to help evaluate hospitals.

Crisis tests a business's culture. It also is a good time to create or strengthen a culture.

The risk of long-term use of oral corticosteroids are well known. This research shows that short "bursts" of one to two weeks also carry some risk of adverse events.

Almost 40% of trials are designed to have fewer than 100 patients.

Researchers cost-impact model calculates the cost to be 15 centers PMPY.

FDA outlines what it will take to get a COVID-19 vaccine approved, while NIH offers its research strategy.

Authors of JAMA Oncology opinion piece see priorities set in response to the pandemic as a chance to discourage low-value cancer care.

Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars. 

Of the 87% of executives who see convergence already happening, 89% say it is accelerating—up from 21% who said the same in 2018.

In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.

The veteran healthcare executive says this may be a Netflix vs. Blockbuster moment for hospitals. And health plans may be under pressure to meet the statutory levels for medical spending and recontract with their networks to offer enhanced payments in return for clinical improvement activities.

More than half of approximately 600 consumers (52%) surveyed in mid-March—the time when major metropolitan areas began issuing “shelter-in-place” orders and encouraging “social distancing”—said they had not been given direct guidance from either their payers or providers regarding the novel coronavirus.

Price of the drug to treat hospitalized patients revealed.

Colorectal cancer drug is the first immunotherapy administered as a first-line treatment and without chemotherapy.

Spotlight report on healthcare discredits the widely held belief that external threats would lead to an increase in data breaches during the COVID-19 pandemic.

"I don't know about you, but in March I was scared; now I'm mostly depressed..."

Data to assess the prevalence and severity of COVID-19 among pregnant U.S. women and determine whether signs and symptoms differ among pregnant and nonpregnant women are limited, according to a report by the CDC.

Company's price is lower than ICER's $50k per-QALY assessment.

An off-the-shelf version of CAR-T therapy that uses the immune system’s natural killer cells is a possibility. But the high price of CAR-T shows some doubts about how widely it can be used.

Penn's David Fajgenbaum, M.D., MBA, is branching out from Castleman disease to assemble comprehensive registry of drugs to treat COVID-19.